Lunit and Summit Test AI Pathology for Ivonescimab Research

Lunit and Summit Therapeutics are collaborating to apply artificial intelligence pathology in the analysis of tumor images as part of research involving ivonescimab. The effort centers on using AI-driven image models to examine tissue samples within the drug’s development program.

The partnership reflects a broader trend in which image-based AI models are being integrated directly into evidence-generation workflows for drug development. By incorporating computational pathology, the companies aim to support the research process for ivonescimab through advanced image analysis.